Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation

• US 20060189941A1
• Filed: 02/28/2006
• Published: 08/24/2006
• Est. Priority Date: 01/22/2002
• Status: Abandoned Application

• Current Assignee: Mercator MedSystems, Inc.
• Original Assignee: Mercator MedSystems, Inc.
• Inventors: Seward, Kirk Patrick, Barr, Lynn Mateel, Cafferata, Robert, Wilber, Judith Carol
• Application Number:
  US11/365,309
• Publication Number:
  US 20060189941A1
• Time in Patent Office: Days
• US Class Current: 604/164.30
• CPC Class Codes: A61M 2025/0096 being laterally outward extensions or tools, e.g. hooks or fibres
• CPC Class Codes: A61M 2025/1086 having a special balloon surface topography, e.g. pores, protuberances, spikes or grooves
• CPC Class Codes: A61M 25/0084 being one or more injection needles
• CPC Class Codes: A61M 25/10 Balloon catheters A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02; inflatable balloons for placing stents or stent-grafts A61F2/958 ; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00

Abstract

Methods and kits for delivering pharmaceutical agents to the adventitia and other regions outside the external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent.

Claims

1. A method for the volumetric distribution of a pharmaceutical agent in the tissue of a living vertebrate host, said method comprising:

positioning a needle through the wall of a target blood vessel so that an aperture of the needle is positioned beyond an external elastic lamina (EEL) of the wall; and

delivering an amount of a pharmaceutical agent comprising an anti-proliferative agent including a macrolide mTOR inhibitor from the aperture so that the agent distributes both longitudinally and radially from the injection site.

2. A method as in claim 1, wherein the macrolide mTOR inhibitor is selected from the group consisting of sirolimus, tacrolimus, everolimus, zotarolimus (ABT-578a), biolimus A9, and pimecrolimus and analogs thereof.

3. A method as in claim 1 or 2, wherein the pharmaceutical agent further comprises an estrogen.

4. A method as in claim 3, wherein the estrogen is selected from the group consisting of 17-β

-estradiol, estradiols valerate, estrone, estriol, and estradiol cypionate.

5. A method as set in claim 1, wherein the agent distributes longitudinally along the blood vessel over a distance of at least 1 cm and radially by a distance of at least 1 cm or within a time period no greater than 60 minutes.

6. A method as in claim 5, wherein the concentrations of agent at all locations spaced at least 2 cm from the delivery site are at least 10% of the concentration at the delivery site.

7. A method as in claim 1, wherein the agent distributes via the lymphatic system surrounding the target.

8. A method as in claim 1, wherein the aperture of the needle is positioned at a distance less than 5 mm beyond the EEL.

9. A method as in claim 8, wherein pharmaceutical agent comprises a small molecule drug, a protein, or a gene.

10. A method as in claim 9, wherein the agent has a maximum dimension of 200 nm or below.

11. A method as in claim 1, wherein the blood vessel is a coronary blood vessel.

12. A method as in claim 6, wherein the coronary blood vessel is an artery.

13. A method as in claim 10, wherein the coronary artery is at risk of hyperplasia.

14. A method as in claim 10, wherein the coronary artery has regions of vulnerable plaque.

15. A method as in claim 1, wherein the patient is suffering from congestive heart failure or a cardiac arrhythmia.

16. A method as in claim 1, wherein the blood vessel is a cerebral blood vessel and the tissue is in the brain of the host.

17. A method as in claim 1, wherein the blood vessel is a hepatic blood vessel and the tissue is in the liver of the host.

18. A method as in claim 1, wherein the agent is being delivered to treat a neoplastic disease in the tissue.

19. A method as in claim 1, further comprising:

confirming that the aperture is positioned beyond the EEL before delivering the amount of pharmaceutical agent.

20. A method as in claim 1, further comprising:

confirming that a delivery aperture of the needle has penetrated into tissue beyond an external elastic lamina (EEL) of the blood vessel before injecting the pharmaceutical agent.

21. An improved method as in claim 20, wherein confirming comprises injecting contrast media through the needle aperture and observing distribution of the media.

22. An improved method as in claim 20, wherein confirming comprises monitoring injection pressure.

23. An improved method as in claim 20, wherein confirming comprises monitoring temperature near the delivery aperture.

24. An improved method as in claim 20, wherein confirming comprises monitoring pH near he delivery aperture.

25. An improved method as in claim 20, wherein confirming comprises monitoring electrical impedance near the delivery aperture.

26. An improved method as in claim 20, wherein confirming comprises monitoring insertion force while positioning the needle through the EEL.

28. A kit as in claim 20, wherein the macrolide mTOR inhibitor is selected from the group consisting of sirolimus, tacrolimus, everolimus, zotarolimus (ABT-578), biolimus A9, and pimecrolimus and analogs thereof.

27. A kit for delivering a pharmaceutical agent to a patient suffering from or at risk of vascular disease, said kit comprising:

a catheter having a needle which can be advanced from a blood vessel lumen through a wall of the blood vessel to position an aperture of the needle beyond an external elastic lamina (EEL) of the wall; and

a pharmaceutical agent injectable through said needle, said agent comprising an anti-proliferative agent including a macrolide mTOR inhibitor.

29. A kit as in claim 27 or 28, wherein the pharmaceutical agent further comprises an estrogen.

30. A kit as in claim 29, wherein the estrogen is selected from the troup consisting of 17-β

-estradiol, estradiols valerate, estrone, estriol, and estradiol cypionate.